meglumine antimoniate + allopurinol

Meglumine antimoniate + allopurinol is a combination therapy used primarily for the treatment of leishmaniasis, including both cutaneous and visceral forms in humans and dogs. Meglumine antimoniate is a pentavalent antimonial compound with antiparasitic activity, though its precise mechanism of action remains incompletely understood; it likely interferes with parasite metabolism and enhances macrophage microbicidal activity. Allopurinol is a purine analog that inhibits RNA synthesis in Leishmania parasites by blocking their ability to utilize purines, thereby inhibiting parasite growth. The combination has demonstrated greater efficacy than either drug alone in clinical studies for both cutaneous and visceral leishmaniasis[1][2][3][4]. This regimen is considered first-line therapy for canine leishmaniasis in Europe[4].

Other names

Glucantime + allopurinol